NASDAQ
No price data available for this timeframe.
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall...
Frontier Capital Management Co. LLC bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) during the second quarter, according to the company in its most recent filing with ...
VANCOUVER, BC , Dec. 11, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to provide further details regarding its ...
Fisher Asset Management LLC trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) by 10.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Ex...
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript...
VANCOUVER, BC , Dec. 2, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to report positive results from its ongoin...
Campbell and CO Investment Adviser LLC bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in the second quarter, according to its most recent disclosure with the SEC. The firm boug...
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs....